BACKGROUND: Congenital sucrase-isomaltase deficiency (CSID) is characterized by absence or deficiency of the mucosal sucrase-isomaltase enzyme. Specific diagnosis requires upper gastrointestinal biopsy with evidence of low to absent sucrase enzyme activity and normal histology. The hydrogen breath test (BT) is useful, but is not specific for confirmation of CSID. We investigated a more specific 13C-sucrose labeled BT. OBJECTIVES: Determine whether CSID can be detected with the 13C-sucrose BT without duodenal biopsy sucrase assay, and if the 13C-sucrose BT can document restoration of sucrose digestion by CSID patients after oral supplementation with sacrosidase (Sucraid). METHODS: Ten CSID patients were diagnosed by low biopsy sucrase activity. Ten controls were children who underwent endoscopy and biopsy because of dyspepsia or chronic diarrhea with normal mucosal enzymes activity and histology. Uniformly labeled 13C-glucose and 13C-sucrose loads were orally administered. 13CO2 breath enrichments were assayed using an infrared spectrophotometer. In CSID patients, the 13C-sucrose load was repeated adding Sucraid. Sucrose digestion and oxidation were calculated as a mean percent coefficient of glucose oxidation averaged between 30 and 90 minutes. RESULTS: Classification of patients by 13C-sucrose BT percent coefficient of glucose oxidation agreed with biopsy sucrase activity. The breath test also documented the return to normal of sucrose digestion and oxidation after supplementation of CSID patients with Sucraid. CONCLUSIONS: 13C-sucrose BT is an accurate and specific noninvasive confirmatory test for CSID and for enzyme replacement management.
BACKGROUND:Congenital sucrase-isomaltase deficiency (CSID) is characterized by absence or deficiency of the mucosalsucrase-isomaltase enzyme. Specific diagnosis requires upper gastrointestinal biopsy with evidence of low to absent sucrase enzyme activity and normal histology. The hydrogen breath test (BT) is useful, but is not specific for confirmation of CSID. We investigated a more specific 13C-sucrose labeled BT. OBJECTIVES: Determine whether CSID can be detected with the 13C-sucrose BT without duodenal biopsy sucrase assay, and if the 13C-sucrose BT can document restoration of sucrose digestion by CSIDpatients after oral supplementation with sacrosidase (Sucraid). METHODS: Ten CSIDpatients were diagnosed by low biopsy sucrase activity. Ten controls were children who underwent endoscopy and biopsy because of dyspepsia or chronic diarrhea with normal mucosal enzymes activity and histology. Uniformly labeled 13C-glucose and 13C-sucrose loads were orally administered. 13CO2 breath enrichments were assayed using an infrared spectrophotometer. In CSIDpatients, the 13C-sucrose load was repeated adding Sucraid. Sucrose digestion and oxidation were calculated as a mean percent coefficient of glucose oxidation averaged between 30 and 90 minutes. RESULTS: Classification of patients by 13C-sucrose BT percent coefficient of glucose oxidation agreed with biopsy sucrase activity. The breath test also documented the return to normal of sucrose digestion and oxidation after supplementation of CSIDpatients with Sucraid. CONCLUSIONS:13C-sucrose BT is an accurate and specific noninvasive confirmatory test for CSID and for enzyme replacement management.
Authors: Petra Sander; Marwan Alfalah; Markus Keiser; Ilma Korponay-Szabo; Judit B Kovács; Tosso Leeb; Hassan Y Naim Journal: Hum Mutat Date: 2006-01 Impact factor: 4.878
Authors: Martin T Christian; Sergio Amarri; Fabio Franchini; Tom Preston; Douglas J Morrison; Brian Dodson; Christine A Edwards; Lawrence T Weaver Journal: J Pediatr Gastroenterol Nutr Date: 2002-02 Impact factor: 2.839
Authors: Roberto Quezada-Calvillo; Claudia C Robayo-Torres; Zihua Ao; Bruce R Hamaker; Andrea Quaroni; Gary D Brayer; Erwin E Sterchi; Susan S Baker; Buford L Nichols Journal: J Pediatr Gastroenterol Nutr Date: 2007-07 Impact factor: 2.839
Authors: Claudia C Robayo-Torres; Marisela Diaz-Sotomayor; Bruce R Hamaker; Susan S Baker; Bruno P Chumpitazi; Antone R Opekun; Buford L Nichols Journal: J Pediatr Gastroenterol Nutr Date: 2018-06 Impact factor: 2.839
Authors: Bruno P Chumpitazi; Claudia C Robayo-Torres; Antone R Opekun; Buford L Nichols; Hassan Y Naim Journal: J Pediatr Gastroenterol Nutr Date: 2012-11 Impact factor: 2.839
Authors: Jason L Eccleston; Christopher Koh; Thomas C Markello; William A Gahl; Theo Heller Journal: Mol Genet Metab Date: 2012-10-23 Impact factor: 4.797
Authors: Jutta Keller; Heinz F Hammer; Paul R Afolabi; Marc Benninga; Osvaldo Borrelli; Enrique Dominguez-Munoz; Dan Dumitrascu; Oliver Goetze; Stephan L Haas; Bruno Hauser; Daniel Pohl; Silvia Salvatore; Marc Sonyi; Nikhil Thapar; Kristin Verbeke; Mark R Fox Journal: United European Gastroenterol J Date: 2021-06-14 Impact factor: 4.623